H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on VANI stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen’s rating is based on the promising potential of Vivani Medical’s NPM-139, a semaglutide implant designed for chronic weight management. The company is preparing to initiate a Phase 1 clinical trial in the first half of 2026, which aims to assess the safety and efficacy of NPM-139. This trial is crucial as it will inform the design of a subsequent Phase 2 trial, with the ultimate goal of advancing to a Phase 3 trial if results are favorable.
Additionally, preclinical studies have shown that NPM-139 can maintain significant weight loss for over six months, suggesting the possibility of annual dosing. This could offer a more convenient alternative to existing treatments like Wegovy, potentially improving patient compliance and reducing discontinuation due to side effects. Furthermore, recent financial activities have bolstered the company’s cash position, although additional capital may be required in the future. These factors collectively contribute to the Buy rating and a price target of $4.
Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, VolitionRX, and Formycon AG. According to TipRanks, Chen has an average return of -6.9% and a 39.44% success rate on recommended stocks.
In another report released on November 14, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.